Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin-assisted psychotherapy for hospitalized treatment-resistant depression
2022-501857-35-00Phase 2Authorised
- Sponsor
- Ghent University Hospital
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of PEX010 in treatment-resistant depression (TRD) and major depressive disorder (MDD), sponsored by Ghent University Hospital. Primary endpoint: Safety during hospitalization phase. Planned start Apr 2024; status: authorised.
02
Drugs
PEX010
03
Conditions
treatment-resistant depression (TRD)major depressive disorder (MDD)
Beyond the preview
Go deeper on 2022-501857-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501857-35-00.